MCET -MultiCell Technologies, Inc.

[Hot Christian Stocks]

MultiCell Technologies, Inc., is a leading provider of liver cell-based products for drug discovery and therapeutic applications. The Company specializes in innovative cell immortalization technologies for reproducible creation of highly functional cell lines. MultiCell is now marketing liver cell lines via licensee, XenoTech, LLC and has additional pipeline products.

Contact Info
68 Cumberland Street
Suite 301
Woonsocket, RI 02895

Website: www.multicelltech.com
Phone: [phone]
Email: [e-mail]

www.otcmarkets.com/stock/MCET/company-info

Management & Board of Directors

W. Gerald Newmin, Chairman of the Board, CFO and
Acting President and CEO
Mr. W. Gerald Newmin joined the Company in June 1995. Mr. Newmin currently serves as Chairman of the Board of Directors and Acting Chief Executive Officer of the Company. Mr. Newmin is also Chairman and CEO, and a director of Xenogenics Corporation, a majority-owned subsidiary of the Company; Chairman and CEO, and a director of MCT Rhode Island Corp., a wholly-owned subsidiary of the Company; and, CEO and a director of MultiCell Immunotherapeutics, Inc., a majority-owned subsidiary of the Company. Mr. Newmin has managed NYSE and American Stock Exchange Fortune 500 companies. Mr. Newmin has been President of Health America Corporation, then the nation’s largest publicly held HMO management company. Mr. Newmin was Chief Executive Officer and President of The International Silver Company, a diversified multi-national manufacturing company that he restructured. Mr. Newmin was Chief Operating Officer of numerous Whittaker Corporation operating units, including Production Steel Company, Whittaker Textiles, Bertram Yacht, Trojan Yacht, Columbia Yacht, Narmco Materials and Anson Automotive. Mr. Newmin was instrumental in Whittaker’s entry into the US and international health care markets. Mr. Newmin was Western Regional Vice President of American Medicorp, Inc, where he managed 23 acute care hospitals in the Western United States. Mr. Newmin retired as Chairman and Chief Executive Officer of SYS Technologies, Inc., a high-growth defense technology company in 2003. Mr. Newmin has a Bachelors degree in Accounting from Michigan State University.

Scott Lukeman, Ph.D., Director
Dr. Lukeman, appointed to the Board in 2012, received his Ph.D. in Pharmacology/Cellular and Molecular Biology from the University of Miami, after earning a B.A. in Natural Sciences from New College of Florida. He has over 25 years of international experience across multiple life-science disciplines in management, strategic planning, business and technology valuation and development, marketing, licensing, fund-raising and competitive intelligence. He has been an executive and strategic consultant with Telios Pharmaceuticals, Italfarmaco, Commtech Venture Group, Inavisis, yet2.com, The Dunn Group, Phoenix PharmaLabs, and other emerging businesses.

Grant Miller, Director
Mr. Miller, appointed to the Board in 2012, received his B.A. from Loma Linda University in Riverside, CA and an MBA in Finance from the University of San Diego, in San Diego, CA. Mr. Miller is Chief Financial & Operating Officer of Sandel Avionics and has served as Chief Financial Officer of Rapid Bridge, LLC, General Manager & Division Controller of Scubapro, Chief Financial Officer of USA Broadband, Inc., Chief Financial Officer & Senior VP Operations of Alitum, and held several positions with WorldXchange and Time Warner Cable, including International Director of Development in Spain and Portugal, Regional Vice President Finance, Corporate Mergers & Acquisitions Analyst, Manager, Finance and Information Systems and Financial Analysis.

Stephen M. Chang, Ph.D., Director
Dr. Stephen Chang has served as a director of the Company since June 2004. Dr. Chang has been Chief Scientific Officer (CSO) of Stemgent, Inc. since January 2008. Prior to joining Stemgent, Dr. Chang served as President and CEO of MultiCell from July 2006 until December 2007, and as President of MultiCell from September 2005 to June 2006. Prior to joining Multicell, Dr. Chang was the CEO of Astral Immunotherapy which was acquired by Multicell Technologies in September 2005. Prior to joining Astral, Dr. Chang was CSO and vice president of Canji Inc. / Schering Plough Research Institute in San Diego from 1998 to 2004. Dr. Chang has also held senior management positions at Chiron and Viagene. Dr. Chang is currently president of CURES, a coalition of patient advocates, biotechnology companies, pharmaceutical companies, and venture capitalists dedicated to ensuring the safety, research, and development of innovative life saving medications. Dr. Chang is also a board member of Histogen a privately held company in regenerative medicine. Dr. Chang earned his doctoral degree in biological chemistry, molecular biology, and biochemistry from the University of California, Irvine.

Thomas A. Page, Director
Mr. Thomas Page has served as a director of the Company since September 2003. Mr. Page is Director Emeritus and former Chairman of the Board and CEO of Enova Corporation and San Diego Gas and Electric Company (now part of Sempra Energy). Prior to the formation of Sempra Energy Corporation as a holding company in 1996, at various times Mr. Page was SDG&E’s chairman, president and CEO and held one or more of these positions until his retirement in 1998. Mr. Page joined SDG&E in 1978 as executive vice president and COO. In 1981, he was elected president and CEO and added the chairmanship in 1983. Mr. Page has been active in numerous industrial, community and governmental associations and has funded medical research. He is a director of the San Diego Regional Economic Development Corporation, Community National Bank, Sys Technologies and is an advisory director of Sorrento Ventures. Mr. Page earned a Bachelor of Science degree in civil engineering, a masters degree in industrial administration and was awarded a doctorate in management, all from Purdue University. Mr. Page has been licensed as an engineer and as a certified public accountant (CPA). Mr. Page also serves on the University of California Presidents Council on the National Laboratories.

Edward Sigmond, Director
Mr. Edward Sigmond has served as a director of the Company since May 2000. Mr. Sigmond has been in sales, marketing and operations management for the past 20 years. Mr. Sigmond has served as president of Kestrel Holdings, Inc., a holding company, since its inception in 1997. Mr. Sigmond served as president of Kestrel Development, a Texas based real estate development company, from 1993 to 1998 when it was dissolved. Mr. Sigmond studied Marketing and Chemistry at Duquesne University.

Therapeutic Pipeline

MultiCell Technologies’ portfolio of lead drug candidates is in various stages of preclinical and clinical development:
MCT-125, a Phase 2 therapeutic candidate for the treatment of PMSF which has demonstrated efficacy in a 138 patient Phase IIa clinical trial.
MCT-465, a preclinical synthetic dsRNA therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers such as those expressing TLR-3.
MCT-475, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of certain cancers.
MCT-485, a discovery stage dsRNA therapeutic candidate for the treatment of certain cancers.

Discovery Platform & Disease Targets
MultiCell Technologies’ discovery platform is focused on approaches to yield innovative targets and therapeutic strategies, and is based on patented technologies which:

Modulate the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF) affecting over 70% of all persons with multiple sclerosis.
Control the immune response at transcriptional and translational levels through double-stranded RNA (dsRNA)-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, to treat cancer.
Enhance antigen presentation to the immune system by targeting antigen epitopes for optimal processing via the Fcg receptors through the novel generation of recombinant immunoglobulins for the treatment of cancer.

Enable generation and manipulation of normal or cancerous stem cells applicable to discovery, design, development of new therapies, diagnostics, and research tools for liver diseases.

Discovery Platform Advantages & Disease Targets
Our therapeutic development platform has several competitive advantages:

The ability to increase the production of adrenaline by selectively modulating noradrenergic neurons with little or no effect on seratoninergic neurons thereby inhibiting the reuptake of noradrenaline (norepinephrine) while promoting increased tyrosine hydroxylase activity, a key regulatory enzyme in noradrenaline/adrenaline biosynthesis pathway. MCT-125, an innovative drug combination currently in Phase 2b clinical development for the treatment of primary multiple sclerosis-related fatigue (PMSF) is based on this technology.
Unlike other immune modulating compounds, our novel synthetic double-stranded RNA (dsRNA) can specifically control the immune response through Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or act directly on cancer cells, affording it the potential for use in a broader spectrum of therapeutic applications in oncology and beyond. This concept has yielded two investigational agents: (i) MCT-465 a high molecular weight dsRNA immune enhancing agent for the treatment of cancer; and (ii) MCT-485, a low molecular weight dsRNA anti-tumor cytotoxic agent for the treatment of certain cancers.
Our therapeutic antibody technology, Epitope-based T-cell Immunotherapy, can more effectively deliver epitope peptides to the immune system than traditional methods. Coupling our synthetic dsRNA platform technology with our therapeutic antibody technology, maximizes the potential of disease-associated epitope peptides, creating more effective anticancer therapeutics. MCT-475 as an investigational therapeutic antibody agent used in conjunction with MCT-465 for the treatment of various cancers such as breast carcinoma.

The ability to isolate and characterize normal stem cells from liver, and potentially isolate and characterize cancer stem cells from liver tumor cells, as discovery tools to support identification of novel therapeutic targets for the treatment of primary hepatocellular carcinoma.